Enlivex reports promising six-month data for Allocetra in knee osteoarthritis

Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response

Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival

Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance

Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma

FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma

Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025

Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis

AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials

Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body